Non-cardiac adverse effects of antihistamines (H1-receptor antagonists)

Clinical and Experimental Allergy, Supplement

Volumn 29, Issue 3, 1999, Pages 125-132

  Simons, F E R ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

Author keywords

CNS effects; H1 antagonists; Neurotransmitter functions

Indexed keywords

CHLORPHENIRAMINE; HISTAMINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADVERSE DRUG REACTION; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DROWSINESS; HUMAN; NEUROTRANSMISSION; PRIORITY JOURNAL; SOMNOLENCE;

EID: 0032810612     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1999.0290s3125.x     Document Type: Article

References (61)

1. Simons FER. Antihistamines. In: Middleton E Jr, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, eds. Allergy Principles and Practice. St Louis: Mosby-Year Book, Inc., 1998; 612-37.
2. 1 receptor activation reduces a background leakage potassium current. Neuroscience 1994; 59:579-88.
3. Panula P, Airaksinen MS, Pirvola U, Kotilainen E. A histamine-containing neuronal system in human brain. Neuroscience 1990; 34:127-32.
4. Prell GD, Green JP, Kaufmann CA, et al. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: their relationship to levels of other aminergic transmitters and ratings of symptoms. Schizophrenia Res 1995; 14:93-104.
5. Panula P, Rinne J, Kuokkannen K, et al. Neuronal histamine deficit in Alzheimer's Disease. Neuroscience 1998; 82:993-7.
6. Leurs R, Smit MJ, Timmerman H. Molecular Pharmacological aspects of histamine receptors. Pharmacol Ther 1995; 66:413-63.
7. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M. Histaminergic transmission in the mammalian brain. Physiol Rev 1991; 71:1-51.
8. Wada H, Inagaki N, Yamatodani T. Is the histaminergic neuron system a regulatory center for whole-brain activity? Trends Neurosci 1991; 14:415-8.
9. 1-antihistaminic agents in relation to their central sedative side-effects. Eur J Pharm Sci 1994; 2:373-84.
10. 1-antagonists and lipophilic basic drugs. Pharmaceut Res 1994; 11:1516-8.
11. Calder JA, Ganellin CR. Predicting the brain-penetrating capability of histaminergic compounds. Drug Des Discov 1994; 11:259-68.
12. 11C] pyrilamine and positron emission tomography. J Neurochem 1992; 59:128-36.
13. 1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Meth Find Exp Clin Pharmacol 1995; 17:64-9.
14. 1 antagonists measured by positron emission tomography. Br J Pharmacol 1995; 116:1649-55.
15. 1-receptor antagonism: studies in man with the enantiomers of chlorpheniramine and dimethindene. Br J Pharmacol 1991; 104:270-6.
16. Snyder SH, Snowman AM. Receptor effects of cetirizine. Ann Allergy 1987; 59:4-8.
17. Kupfer DJ, Reynolds CF III. Management of insomnia. N Engl J Med 1997; 336:341-6.
18. Darcis T, Ferreri M, Natens J, Burtin B, Deram P, and the French GP Study Group for Hydroxyzine. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol Clin Exp 1995; 10:181-7.
19. Vener DF, Carr AS, Sikich N, Bissonnette B, Lerman J. Dimenhydrinate decreases vomiting after strabismus surgery in children. Anesth Analg 1996; 82:728-31.
20. Mitchelson F. Pharmacological agents affecting emesis. A review (Part I). Drugs 1992; 43:295-315.
21. Truong DD, Sandroni P, van den Noort S, Matsumoto RR. Diphenhydramine is effective in the treatment of idiopathic dystonia. Arch Neurol 1995; 52:405-7.
22. 1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995; 6:1475-9.
23. 1-receptor antagonists. Clin Exp Allergy 1994; 24:707-23.
24. 1-receptor antagonists. Comparative tolerability and safety. Drug Safety 1994; 10:350-80.
25. Rombaut NEI, Hindmarch I. Psychometric aspects of antihistamines: a review. Hum Psychopharmacol Clin Exp 1994; 9:157-69.
26. Simons FER. The eternal triangle: benefit, risk, and cost of therapeutic agents. Ann Allergy Asthma Immunol 1996; 77:337-40.
27. Klein GL, Littlejohn III T, Lockhart EA, Furey SA. Brompheniramine, terfenadine, and placebo in allergic rhinitis. Ann Allergy Asthma Immunol 1996; 77:365-70.
28. Falliers CJ, Brandon ML, Buchman E, et al. Double-blind comparison of cetirizine and placebo in the treatment of seasonal rhinitis. Ann Allergy 1991; 66:257-62.
29. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol 1995; 96:139-47.
30. Vuurman EFPM, van Veggel LMA, Uiterwijk MMC, Leutner D, O'Hanlon JF. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993; 71:121-6.
31. Walsh JK, Muehlbach MJ, Schweitzer PK. Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992; 69:195-200.
32. 1-antihistamine, cetirizine. Aviat Space Environ Med 1998; 69:166-71.
33. Valk PJ, Simons RM, Struyvenberg PA, Kruit H, van Berge Henegouwen MT. Effects of a single dose of loratadine on flying ability under conditions of simulated cabin pressure. Am J Rhinol 1997; 11:27-33.
34. Ramaekers JG, O'Hanlon JF. Acrivastine, terfenadine and diphenhydramine effects on driving performance as a function of dose and time after dosing. Eur J Clin Pharmacol 1994; 47:261-6.
35. 1-histamine receptor antagonist ebastine in 10, 20, and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993; 36:67-70.
36. Vermeeren A, O'Hanlon JF. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998; 101:306-11.
37. Hindmarch I, Bhatti JZ. Psychomotor effects of astemizole and chlorpheniramine, alone and in combination with alcohol. Int Clin Psychopharmacol 1987; 2:117-9.
38. Goetz DW, Jacobsen JM, Murnane JE, et al. Prolongation of simple and choice reaction times in a double-blind comparison of twice-daily hydroxyzine versus terfenadine. J Allergy Clin Immunol 1989; 84:316-22.
39. Patat A, Perault MC, Vandel B, Ulliac N, Zieleniuk I, Rosenzweig P. Lack of interaction between a new antihistamine, mizolastine, and lorazepam on psychomotor performance and memory in healthy volunteers. Br J Clin Pharmacol 1995; 39:31-8.
40. Goetz DW, Jacobson JM, Apaliski SJ, Repperger DW, Martin ME. Objective antihistamine side effects are mitigated by evening dosing of hydroxyzine. Ann Allergy 1991; 67:448-54.
41. Starbuck VN, Kay GG, Platenberg RC. Functional magnetic resonance imaging shows evidence of daytime sleepiness following evening dosing with chlorpheniramine. J Allergy Clin Immunol 1998; 101:S97.
42. Schweitzer PK, Muehlbach MJ, Walsh JK. Sleepiness and performance during three-day administration of cetirizine or diphenhydramine. J Allergy Clin Immunol 1994; 94:716-24.
43. Stanley N, Alford CA, Rombaut NEI, Hindmarch I. Comparison of the effects of astemizole/pseudoephedrine and triprolidine/pseudoephedrine on CNS activity and psychomotor function. Int Clin Psychopharmacol 1996; 11:31-6.
44. Alford C, Romabaut N, Jones J, et al. Acute effects of hydroxyzine on nocturnal sleep and sleep tendency the following day: a C-EEG study. Hum Psychopharmacol Clin Exp 1992; 7:25-35.
45. Seidel WF, Cohen S, Bliwise NG, Dement WC. Direct measurement of daytime sleepiness after administration of cetirizine and hydroxyzine with a standardized electroencephalographic assessment. J Allergy Clin Immunol 1990; 86:1029-33.
46. Roehrs T, Zwyghuizen-Doorenbos A, Roth T. Sedative effects and plasma concentrations following single doses of triazolam, diphenhydramine, ethanol and placebo. Sleep 1993; 16:301-5.
47. 1-receptor antagonists). Ann Allergy Asthma Immunol 1995; 75:507-14.
48. 1-receptor antagonists. Clin Exp Allergy 1996; 26:1092-7.
49. 1-receptor antagonists) terfenadine and chlprpheniramine in children. J Pediatr 1994; 124:979-83.
50. Gilmore TM, Alexander BH, Mueller BA, Rivara FP. Occupational injuries and medication use. Am J Industr Med 1996; 30:234-9.
51. Su L, Guess HA, Girman CJ, et al. Adverse effects of medications on urinary symptoms and flow rate: a community-based study. J Clin Epidemiol 1996; 49:483-7.
52. Kahn A, Blum D. Phenothiazines and sudden infant death syndrome. Pediatrics 1982; 70:75-8.
53. Lijinsky W, Reuber MD, Blackwell B-N. Liver tumors induced in rats by oral administration of the antihistamine methapyrilene hydrochloride. Science 1980; 209:817-9.
54. Brandes LJ, Friesen LA. Can the clinical course of cancer be influenced by non-antineoplastic drugs? Can Med Assoc J 1995; 153:561-6.
55. 1-antihistamines: predictive in vitro correlates. J Nat Cancer Inst 1994; 86:770-5.
56. Mathews J. Concern over Prozac-induced tumor growth may dwindle following FDA study. J Nat Cancer Inst 1995; 87:1285-7.
57. Hait WN, Gesmonde JF, Murren JR, et al. Terfenadine (Seldane): a new drug for restoring sensitivity to multidrug resistant cancer cells. Biochem Pharmacol 1993; 45:401-6.
58. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: 11 to 15 years of follow-up. Cancer Res 1989; 49:5736-47.
59. 1 histamine antagonists. Reprod Toxicol 1996; 10:247-55.
60. Schatz M, Petitti D. Antihistamines and pregnancy. Ann Allergy Asthma Immunol 1997; 78:157-9.
61. Koren G. Drugs in pregnancy. N Engl J Med 1998; 338:1128-37.